


A global education platform providing clinical updates on acute myeloid leukemia. Intended for HCPs. linktr.ee/AcuteMyeloidLeukem… #leusm


🎥 The AML Hub was pleased to speak with Emma Searle. We asked, What have we learned from emerging next-generation menin inhibitor data, and how are they evolving? Watch the full video here: bit.ly/4j5PpkS #AMLsm #leusm #MedEd Intended for healthcare professionals. Independently supported by Johnson & Johnson. Funders are allowed no influence.


🎥 The AML Hub was pleased to speak with Joshua Zeidner. We asked, What progress has been made with first-generation menin inhibitors in AML, and what needs remain? Watch the full video here: bit.ly/4zOzoH1 #AMLsm #leusm #MedEd Intended for healthcare professionals. Independently supported by Johnson & Johnson. Funders are allowed no influence.


New publication 📝 Results from a retrospective analysis, published in @BloodAdvances, show Grade 4 neutropenia at baseline was associated with prolonged neutropenia during azacitidine + venetoclax induction in patients with ND AML. Learn more about ND AML: bit.ly/3NSE3Vk #AMLsm #leusm #MedNews #MedEd

🚨 NEWS 🚨 @BloodCancerUtd launches Dare to Dream REALworld: AML, a patient-centered initiative that will engage current and former pediatric patients with AML and their families to build a dataset of real-world evidence to inform research and future clinical trials. Read more: bit.ly/3VkqKRx #AMLsm #leusm #MedNews #MedEd

New publication 📝Results from a retrospective study, published in @LeukemiaJnl, show Ven-based therapy significantly improved median OS vs HMA monotherapy in patients with ND AML ineligible for intensive chemotherapy (11.4 vs 8.2 months; HR, 0.66; p < 0.001). Learn more about ND AML: bit.ly/3NSE3Vk #AMLsm #leusm #MedNews #MedEd

Personalize your AML Hub experience by creating a My AML Hub account. ▪️ Bookmark articles ▪️ Select your areas of interest ▪️ View recommended content Create your account here: bit.ly/4sd8Zj0 #amlsm #leusm #acutemyeloidleukemia

🎥 Eunice Wang discusses potential future applications of menin inhibitors for the treatment of AML, including in sequential treatment approaches and integration into combination regimens. Watch the full video here: bit.ly/3X18qNF #AMLsm #leusm #MedEd Intended for healthcare professionals. Independently supported by Johnson & Johnson. Funders are allowed no influence.


New publication 📝 Results from an EBMT registry study, published in @BMTjournal, show that ATG demonstrated superior 3-year OS (58.3% vs 50.4%; p = 0.03) vs alemtuzumab when used as GvHD prophylaxis in adults with AML undergoing allo-HSCT from unrelated donors with intermediate-intensity conditioning. Learn more about allo-HSCT in AML: bit.ly/4tj1Wp3 #AMLsm #leusm #MedNews #MedEd

🎥 The AML Hub was pleased to speak with Eunice Wang. We asked, What does the future hold for next-generation menin inhibition in AML? Watch the full video here: bit.ly/3X18qNF #AMLsm #leusm #MedEd Intended for healthcare professionals. Independently supported by Johnson & Johnson. Funders are allowed no influence.

New publication 📝 The trial design and rationale for the phase III QuANTUM-Wild trial, evaluating quizartinib + intensive chemotherapy in patients with ND FLT3-ITD-negative AML, were published in Future Oncology. Learn more about FLT3 inhibition in AML: bit.ly/3TWw10D #AMLsm #leusm #MedNews #MedEd


New publication 📝 An updated SITC clinical practice guideline, published in @jitcancer, provides evidence- and consensus-based recommendations on immunotherapy for AML, including risk-adapted treatment approaches. Learn more about AML: bit.ly/4keAq8j #AMLsm #leusm #MedNews #MedEd